BELKIN Vision
BELKIN Vision is an Israeli medical device company that developed automated Direct Selective Laser Trabeculoplasty (DSLT) technology for first-line glaucoma treatment, serving ophthalmologists and glaucoma specialists. The company was acquired by Alcon in July 2024 for $466 million.
- Company typePrivate
- Founded2013
- HeadquartersYavne, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BELKIN Vision does
BELKIN Vision is an Israeli medical device company founded in 2013 and headquartered in Yavne that developed Direct Selective Laser Trabeculoplasty (DSLT) technology for the treatment of glaucoma. The company's core system automates the delivery of 120 laser pulses directly through the limbus to the trabecular meshwork, improving aqueous outflow and reducing intraocular pressure without requiring a gonio lens, thereby simplifying the procedure workflow for ophthalmologists and glaucoma specialists.
The company's primary product, now marketed as the Voyager DSLT system, addresses open-angle glaucoma and ocular hypertension as a first-line intervention. Clinical evidence cited by the company shows 62% of DSLT patients were medication-free at 12 months, 81% were on the same or fewer medications, and zero ocular serious adverse events were recorded through 12 months. The technology is recognized as an effective primary intervention by the American Academy of Ophthalmology, the European Glaucoma Society, and NICE, providing a regulatory and guideline-backed moat.
BELKIN Vision operated as a privately held company raising approximately $38.6 million across three funding rounds between 2017 and 2021 from investors including the European Innovation Council, Rimonci Capital, Santen Ventures, C-Mer Eye Care, and BioLight. In July 2024, Alcon acquired BELKIN Vision for $466 million, integrating DSLT into Alcon's professional glaucoma product portfolio. Following the acquisition, BELKIN Vision no longer operates as an independent entity and its technology is commercialized through Alcon's global medical device distribution network.
BELKIN Vision firmographics
Firmographics- Name
- BELKIN Vision
- Legal name
- BELKIN Vision
- Website
- https://belkin-vision.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- BELKIN Vision is an Israeli medical device company that developed automated Direct Selective Laser Trabeculoplasty (DSLT) technology for first-line glaucoma treatment, serving ophthalmologists and glaucoma specialists. The company was acquired by Alcon in July 2024 for $466 million.
- Ownership category
- akta.pro rank
BELKIN Vision industry classification
Industry- Product category
- Ophthalmic Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)
- akta.pro secondary industry
- Glaucoma Specialists (HLAKAKAG)
Keywords
Where BELKIN Vision is headquartered
LocationHeadquarters
- HQ city
- Yavne
- HQ country
- Israel
- HQ region
- Middle East
Markets served
BELKIN Vision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
BELKIN Vision product offering
Product offeringCore offering
BELKIN Vision developed the Direct Selective Laser Trabeculoplasty (DSLT) medical laser system for ophthalmologists and glaucoma specialists to treat open-angle glaucoma and ocular hypertension. The Voyager DSLT device automatically delivers 120 laser pulses through the limbus to the trabecular meshwork in a gonio-free procedure, reducing intraocular pressure and medication burden. Following Alcon's $466 million acquisition in July 2024, the technology is commercialized within Alcon's professional glaucoma portfolio.
Product overview
BELKIN Vision specialized in medical laser technology for glaucoma treatment, offering the Direct Selective Laser Trabeculoplasty (DSLT) system. The company was acquired by Alcon in July 2024 for $466 million, and its technology is now sold as the Voyager DSLT product within Alcon's professional glaucoma portfolio.
Differentiator
Problem solved
Functional benefit
Products and services
- Voyager™ DSLT (Direct Selective Laser Trabeculoplasty) Medical laser system that automatically delivers 120 laser pulses directly through the limbus to the trabecular meshwork in a gonio-free procedure to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension; intended for ophthalmologists and glaucoma specialists.
Quantifiable outcome
- 62% of all DSLT patients were medication-free at 12 months
- +5 more outcomes
Companies that use BELKIN Vision
Customer profileSegments2 records
Ideal customer profiles2 records
BELKIN Vision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
BELKIN Vision partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights4 records
BELKIN Vision competitors and assessment
Company assessmentDirect peers
- Iridex Corporation: Markets laser systems for glaucoma treatment, including transscleral cyclophotocoagulation and SLT-adjacent offerings. Overlaps with BELKIN in physician-targeted laser glaucoma therapy, though with different delivery modalities.
- Quantel Medical: Subsidiary of Lumibird that manufactures ophthalmic lasers including traditional SLT systems (e.g., Optimis, Vitra). It is the closest direct competitor to BELKIN's DSLT, addressing the same glaucoma treatment workflow with manual SLT delivery.
- Lumenis (BE Laser): Historical pioneer of SLT technology (Selecta II) and a long-standing provider of ophthalmic lasers for glaucoma. Remains a direct competitor to DSLT in the same physician workflow for IOP reduction.
- Topcon Healthcare: Producer of the Tango SLT and other ophthalmic lasers used in glaucoma management. Topcon competes with BELKIN for the same ophthalmologist and glaucoma specialist customers performing laser-based IOP reduction.
- Nidek: Japanese ophthalmic device manufacturer offering SLT lasers (e.g., YC-1800 SLP) and a broader portfolio of glaucoma diagnostic and treatment devices, directly overlapping with BELKIN's physician customer base and procedural category.
Broad incumbents
- Glaukos Corporation: Market leader in MIGS devices (iStent) for glaucoma. Competes with BELKIN for the same patient population and physician mindshare, but via an implantable surgical approach rather than a laser-based one.
- Carl Zeiss Meditec: Diversified ophthalmic equipment manufacturer with diagnostics, surgical microscopes, and laser offerings including SLT-capable platforms. Competes broadly in the ophthalmologist's clinic where BELKIN's DSLT would be adopted.
- Sight Sciences: Commercial-stage ophthalmic device company with the OMNI and TearCare systems, including MIGS offerings targeting the same glaucoma treatment pathway that DSLT addresses as a non-invasive alternative.
- Nova Eye Medical: Glaucoma-focused device company offering the iTrack canaloplasty microcatheter and the Molteno3 drainage implant. Addresses the same glaucoma surgical treatment workflow as DSLT and competes for procedural slots with ophthalmic surgeons.
Others
- Heidelberg Engineering: Provider of diagnostic imaging (OCT, HRT) used in glaucoma diagnosis and management. Adjacent to BELKIN's workflow rather than directly competitive, but relevant as part of the broader glaucoma care ecosystem in which DSLT is deployed.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
BELKIN Vision social profiles
Digital presenceBELKIN Vision financial estimates
Financial estimateRevenue estimate
Valuation estimate
BELKIN Vision leadership team
Management profileNumber of profiles
Profiles7 records
BELKIN Vision funding detail
Funding detailFunding overview
Funding rounds4 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BELKIN Vision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BELKIN Vision
What does BELKIN Vision do?
BELKIN Vision developed the Direct Selective Laser Trabeculoplasty (DSLT) medical laser system for ophthalmologists and glaucoma specialists to treat open-angle glaucoma and ocular hypertension. The Voyager DSLT device automatically delivers 120 laser pulses through the limbus to the trabecular meshwork in a gonio-free procedure, reducing intraocular pressure and medication burden. Following Alcon's $466 million acquisition in July 2024, the technology is commercialized within Alcon's professional glaucoma portfolio.
Is BELKIN Vision a public or private company?
BELKIN Vision is a private company. It is classified as corporate owned and is currently acquired.
When was BELKIN Vision founded?
BELKIN Vision was founded in 2013. It employs 11 to 50 people.
Where is BELKIN Vision based?
BELKIN Vision is headquartered in Yavne, Israel, in the Middle East region.
Who are BELKIN Vision's main competitors?
Direct peers on record are Iridex Corporation, Quantel Medical, Lumenis (BE Laser), Topcon Healthcare and Nidek. Broad incumbents are Glaukos Corporation, Carl Zeiss Meditec, Sight Sciences and Nova Eye Medical. Heidelberg Engineering is listed as an others.
Does BELKIN Vision have an API?
No public API is recorded for BELKIN Vision.
What industry is BELKIN Vision in?
BELKIN Vision's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAI, Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty), with a secondary code of HLAKAKAG, Glaucoma Specialists. Its NAICS code is 339112 and its SIC code is 3841.